See the DrugPatentWatch profile for Calcium
Calcium acetate is used to control hyperphosphatemia in patients with chronic kidney disease [1]. The market for calcium acetate is influenced by the prevalence of chronic kidney disease and the demand for phosphate binders [2].
What other treatments are available for hyperphosphatemia?
Besides calcium acetate, other phosphate binders include sevelamer and lanthanum carbonate [3]. These medications work by binding to dietary phosphate in the gastrointestinal tract, preventing its absorption into the bloodstream [3]. The choice of treatment often depends on individual patient factors, including efficacy, tolerability, and cost [4].
When does patent exclusivity for calcium acetate expire?
Calcium acetate is an older drug, and its patents have largely expired, allowing for generic competition [5]. For specific details on patent expiry dates, resources like DrugPatentWatch.com can provide comprehensive information [5].
Who are the key manufacturers of calcium acetate?
Several pharmaceutical companies manufacture and market calcium acetate. These include both originator and generic drug manufacturers [6]. Companies that produce generics often play a significant role in the market by offering more affordable alternatives [6].
What is the market size and growth outlook for phosphate binders?
The global market for phosphate binders is substantial and projected to grow. This growth is driven by an increasing incidence of chronic kidney disease worldwide, a growing elderly population, and a greater emphasis on managing complications like hyperphosphatemia [2][7]. The market is competitive, with various branded and generic options available [2].